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Abstract	(200	words)	
Cyclists	 in	 the	 Tour	 de	 France	 are	 endurance	 specialists.	 Twin	 and	 family	 studies	 have	
shown	 that	 approximately	 50%	 of	 the	 variance	 in	 a	 number	 of	 performance	 related	
phenotypes	(whether	measured	at	baseline,	 i.e.	natural	 talent,	or	 in	response	to	training)	
including	 those	 important	 to	 cycling	 can	be	explained	by	genetic	 variation.	Research	 into	
the	specific	genetic	variants	that	are	responsible	has	 identified	over	200	genes	containing	
common	genetic	 variants	 involved	 in	 the	 genetic	 predisposition	 to	 physical	 performance.	
However,	 typically	 these	 explain	 only	 a	 small	 portion	 of	 the	 variance,	 perhaps	 1-2%	 and	
collectively	they	rarely	explain	anything	approaching	the	50%	of	the	variance	 identified	 in	
the	 twin	and	 family	 studies.	Thus,	 there	 is	a	gap	 in	our	understanding	of	 the	 relationship	
between	 heritability	 and	 performance.	 This	 gap	may	 be	 bridged	 by	 investigation	 of	 rare	
variants	 or	 epigenetic	 variation	 or	 by	 altering	 study	 designs	 through	 increased	
collaborations	 to	 pool	 exiting	 cohorts	 together.	 Initial	 findings	 from	 such	 efforts	 show	
promising	 results.	This	mini-review	will	 touch	on	 the	genetics	and	epigenetics	of	 sporting	
performance,	 how	 they	 relate	 to	 cyclists	 in	 the	 Tour	 de	 France	 and	 where	 best	 future	
efforts	may	be	directed	as	well	as	discuss	some	preliminary	research	findings.	
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Main	text	
Introduction	
Since	 at	 least	 the	 time	 of	 the	 Ancient	 Greeks	 humans	 have	 challenged	 each	 other	 in	
competitive	 performance	 tasks.	 Concomitantly	 scholars	 have	 attempted	 to	 identify	 the	
determinants	of	performance	and	thus	methods	to	 improve	performance.	Aristotle,	 in	his	
Nicomachean	 Ethics	 (Aristotle,	 2002),	 wrote,	 “both	 excessive	 and	 insufficient	 exercise	
destroy	one's	strength,	and	both	eating	and	drinking	too	much	or	too	little	destroy	health,	
whereas	the	right	quantity	produces,	increases	or	preserves	it.”	Modern	day	sports	science	
maintains	 these	 efforts	 and	 is	 in	 part	 responsible	 for	 the	 continued	 improvements	 in	
performance	 in	 most	 sports	 that	 we	 see	 to	 the	 present	 day.	 In	 cycling	 we	 have	 seen	
improvements	 in	 the	 technology	 of	 the	 bicycle,	 the	 athlete’s	 diet,	 nutritional	 strategies	
during	the	race	and	in	types	and	management	of	training	to	name	only	a	few	of	the	areas	
of	 advancement.	 Competitors	 in	 the	 Tour	 de	 France	 are	 supported	 by	 a	 large	 team	 of	
experts	 including	 Sport	 Scientists,	 Physiotherapists,	 Medics	 and	 Nutritionists.	 However,	
given	the	right	team,	resources	and	training,	the	question	remains	whether	anyone	can	win	
the	Tour	de	 France	or	whether	 champions	are	born	with	 some	 innate	genetic	 advantage	
over	others.		
The	 Tour	 de	 France	 is	 a	 gruelling	 endurance	 event.	 The	 cyclists	 who	 take	 part	 are	
endurance	experts.	Typically	 the	 race	covers	3200-4000	km	and	contains	 long	 flat	 stages,	
shorter	 individual	 time	trials	and	uphill	 stages.	Although	the	cyclists	may	specialise,	or	be	
more	 suited	 to,	 one	 type	 of	 terrain,	 they	 have	 to	 cover	 all	 three	 types	 of	 terrain.	 Their	
characteristics	are	reviewed	in	Lucia,	Hoyos,	&	Chicharro	(2001).	In	summary,	typically	they	
will	 all	 have	 high	 maximal	 power	 output	 (>500	 W)	 in	 incremental	 tests	 with	 1	 minute	
increments,	 high	 power	 to	 weight	 ratio	 (6-7.5	 W/kg),	 high	 maximal	 oxygen	 uptake	
(𝑉𝑂!!"#;	70-80	ml/min/kg)	and	a	high	anaerobic	 threshold	 (~90%	𝑉𝑂!!"#)	although	 the	
precise	 values	 vary	depending	on	 their	 specialism.	Physiologically,	 they	are	 likely	 to	have	
low	body	 fat	 (8-10%),	 large	hearts	 (152	g/m2	mean	ventricular	mass	 index),	 large	arteries	
(~13%	larger	carotid	arteries),	higher	skeletal	muscle	type	I	fibre	content	(Coyle	et	al.,	1991)	
and	 increased	 mitochondrial	 volume	 (Rodríguez	 et	 al.,	 2002).	 Whilst	 many	 of	 these	
characteristics	may	 be	 altered	 by	 training	 (Rivera-Brown	&	 Frontera,	 2012)	 several	 have	
also	been	shown	to	be	influenced	by	genetics	(see	Wolfarth	et	al.,	2014	for	review).	Thus,	
rather	than	ask	whether	Tour	de	France	champions	are	born	or	made	it	is	more	appropriate	
to	 ask	 what	 the	 extent	 is	 of	 the	 influence	 of	 genetics	 on	 the	making	 of	 Tour	 de	 France	
champions.	
Genetic	Variation,	Heritability	and	Performance	
The	 Human	 Genome	 Project	 was	 completed	 over	 a	 decade	 ago	 (Lander	 et	 al.,	 2001).	
However,	 we	 all	 carry	 slightly	 different	 versions	 of	 that	 DNA	 sequence	 and	 in	 terms	 of	
understanding	human	physiology	 the	sequence	differences	between	us	are	as	 interesting	
as	 the	 basic	 sequence	 itself.	 Subsequent	 projects	 such	 as	 the	 HapMap	 (International	
HapMap	 Consortium,	 2005)	 and	 1000genomes	 (Abecasis	 et	 al.,	 2012)	 projects	 have	
provided	 information	on	 the	extent	of	 the	 variation	between	 individuals.	Ultimately,	 it	 is	
clear	that	whilst	human	DNA	sequences	are	highly	similar	(~99%)	there	are	a	large	number	
of	sites	in	our	DNA	at	which	we	vary	(~38	million);	and,	that	the	rate	of	variation	at	these	
sites	has	a	wide	range	with	some	variants	very	common	in	the	population	and	others	very	
rare.	 For	 example,	 the	 minor	 allele	 of	 alpha-actinin-3	 variant	 rs1815739	 has	 a	 global	
frequency	 of	 40%	 whilst	 the	 minor	 allele	 of	 the	 erythropoietin	 receptor	 variant	
rs121917830	has	a	global	frequency	of	<0.001%.	
To	 understand	 how	 these	 genetic	 variants	 relate	 to	 cycling	 performance	 or	 to	 sports	
performance	 in	 general	we	 also	 need	 to	 assess	 human	performance	 variation	 and	 relate	
that	 to	 the	genetic	differences.	However,	 few	studies	 specifically	 investigate	 cyclists.	 In	a	
general	 sense,	 it	 is	 widely	 recognised	 that	 humans	 display	 a	 large	 variation	 in	 physical	
performance	 (e.g.	 Bouchard	 et	 al.,	 1998).	We	 also	 think	 of	 some	 individuals	 as	 naturally	
talented	and	others	as	lacking	in	talent	(Hyllegard,	Radlo,	&	Early,	2001;	Williams	&	Reilly,	
2000).	 Similarly,	 we	 see	 some	 individuals	make	 large	 gains	 in	 performance	with	 training	
whilst	others	 show	 little	or	no	 response	 to	 training	 (Bouchard	et	al.,	1999).	Furthermore,	
individuals	often	excel	at	endurance	based	sports	or	power	based	sports,	but	rarely	both.	In	
part	these	differences	will	result	from	differing	training	modalities	(i.e.	more	sprint	/	power	
or	 endurance)	 and	 opportunities	 for	 sports	 participation.	 However,	 talented	 individuals	
often	come	 from	talented	 families	 (De	Moor	et	al.,	2007)	and	whilst	 families	 share	many	
aspects	of	their	environments,	they	also	share	known	amounts	of	their	DNA	depending	on	
the	 relationship	 between	 the	 specific	 individuals	 in	 question.	 If	 genetic	 variation	 is	 even	
partially	responsible	for	the	physiological	characteristics	important	for	cycling,	then	unique	
combinations	 of	 variants	 are	 likely	 to	 have	 the	 potential	 to	 predispose	 an	 individual	
towards	elite	cycling	ability.	
Twin	 and	 family	 studies	make	use	of	 the	 known	quantity	 of	 shared	DNA	 to	partition	 the	
variance	 in	 performance	 that	 can	 be	 explained	 by	 environmental	 factors	 or	 by	 genetic	
factors.	A	British	twin	study,	which	included	a	small	number	of	cyclists,	found	that	athlete	
status	 runs	 in	 families	 and	 has	 a	 large	 genetic	 component	 (De	Moor	 et	 al.,	 2007).	 If	 we	
focus	on	endurance	capacity,	a	key	aspect	of	cycling	performance,	the	classic	family	study	is	
the	HERITAGE	 study	 (Bouchard	et	al.,	 1998,	1999).	Bouchard	and	colleagues	 recruited	98	
families	 comprised	of	 481	 sedentary	 individuals	 to	 a	 training	 study.	 They	measured	 their	
maximum	aerobic	capacity	(𝑉𝑂!!"#),	then	trained	these	individuals	3	times	a	week	for	20	
weeks	 before	 measuring	 their	 𝑉𝑂!!"#	 again.	 The	 average	 gain	 in	 𝑉𝑂!!"#	 was	
approximately	0.4	L/min	although	there	was	a	very	 large	range	of	values	from	little	or	no	
gain	to	gains	over	1	L/min.		Due	to	the	relatedness	of	the	family	members	they	were	able	to	
estimate	that	approximately	50%	of	the	variance	in	𝑉𝑂!!"#	could	be	explained	by	genetic	
variation	(whether	measured	at	baseline,	i.e.	natural	talent,	or	in	response	to	training).	This	
implies	that	genetic	variation	is	at	least	as	important	to	performance	as	everything	else	put	
together,	i.e.	lifestyle,	diet,	training,	facilities,	etc.	
Common	Genetic	Variants	
Research	 into	the	specific	genetic	variants	 that	are	responsible	 for	 this	genetic	portion	of	
the	variance	has	identified	over	200	genes	containing	common	genetic	variants	involved	in	
the	genetic	predisposition	to	aspects	of	physical	performance	(Wolfarth	et	al.,	2014).	Work	
on	 the	genetics	of	 sporting	performance	has	 involved	cohorts	of	elite	 level	athletes	 from	
around	the	globe	and	from	a	variety	of	sports.	It	includes	Ethiopian	and	Kenyan	endurance	
runners,	 track	 sprinters	 from	 Jamaica	 and	 the	 USA	 and	 both	 endurance	 runners	 and	
sprinters	 from	 Australia,	 Russia,	 and	 Japan.	 However,	 although	 several	 of	 these	 cohorts	
include	endurance	cyclists,	typically	the	number	of	cyclists	is	small	and	very	little	research	
has	 been	 done	 directly	 on	 the	 genetics	 of	 cycling	 performance.	 Contrast	 the	 number	 of	
performance	related	genes	(>200)	with	the	less	than	20	genes	that	have	been	investigated	
in	 cohorts	 containing	 cyclists	 (Table	 1).	 Cyclists	 are	 often	 included	 because	many	 of	 the	
characteristics	 important	 to	 cycling	performance,	 such	as	high	𝑉𝑂!!"#	 or	high	anaerobic	
threshold,	 are	 common	 to	other	endurance	 sports.	 Thus,	 they	are	 included	as	part	of	 an	
endurance	 sports	 group	with	 little	more	 detailed	 information.	 Furthermore,	 it	 is	 rare	 for	
these	 cohorts	 to	 include	 quantitative	 measurements	 of	 all	 the	 key	 performance	
characteristics	 known	 to	 be	 important	 to	 cycling	 performance.	 Obtaining	 quantitative	
measurements	 requires	 more	 of	 the	 athletes’	 time	 and	 thus	 makes	 recruitment	 more	
challenging.	 Consequently,	 most	 of	 what	 is	 known	 about	 the	 genetics	 of	 cycling	
performance	is	inferred	from	other	sports	requiring	similar	physiological	traits.	More,	larger	
studies	including	elite	cyclists	are	warranted.	
Perhaps	 the	 best	 known	 example	 of	 a	 performance	 variant	 is	 alpha-actinin-3	 (ACTN3)	
R577X	(rs1815739)	which	has	been	strongly	linked	to	sprinting	ability	(Moran	et	al.,	2007;	
Yang	et	al.,	2003)	and	less	conclusively	with	endurance	ability	(Alfred	et	al.,	2011).		ACTN3	
is	a	muscle	structural	protein	mostly	found	in	type	2	fibres.	It	is	an	unusual	variant	in	that	
the	X-allele	is	a	nonsense	allele	and	XX	homozygotes	carry	no	functional	ACTN3	whatsoever	
despite	 being	 relatively	 common	 (approximately	 16%	 of	 the	 global	 population,	 ranging	
from	 approximately	 1	 to	 30%	 in	 various	 populations).	 These	 individuals	 survive	 due	 to	
functional	 redundancy	 between	 ACTN3	 and	 alpha-actinin-2	 (ACTN2)	 although	 that	
redundancy	 must	 be	 incomplete	 since	 XX	 homozygotes	 are	 significantly	 less	 likely	 to	
become	 elite	 sprinters.	 This	 and	 similar	 findings	 have	 been	 replicated	 in	 many	 cohorts	
(Berman	&	North,	2010).	Although	a	small	number	of	studies	find	no	association	with	sprint	
/	 power	 performance	 (e.g.	 Rodríguez-Romo	 et	 al.,	 2013),	 it	 is	 likely	 that	 this	 can	 be	
explained	 by	 statistical	 chance	 or	 subject	 differences.	 Conversely,	 the	 X-allele	 has	 been	
linked	 to	 endurance	 capacity	 (Yang	 et	 al.,	 2003)	 although	 somewhat	 less	 conclusively	
(Alfred	 et	 al.,	 2011).	 Three	 studies	 (Table	 1)	 have	 investigated	 the	 association	 between	
ACTN3	 genotype	 and	 endurance	 cycling	 hypothesising	 that	 they	 would	 find	 an	 over-
representation	of	 the	X-allele	 in	elite	 cyclists.	However,	 two	studies	 found	no	association	
and	the	third	found	an	under-representation	of	the	X-allele	in	cyclists.	
Typically,	 these	 common	 genetic	 variants,	 including	 ACTN3	 R577X,	 explain	 only	 a	 small	
portion	of	the	phenotypic	variance,	perhaps	1-2%.	Such	small	effects	are	difficult	to	identify	
without	very	 large	 cohorts.	 This	 is	 compounded	by	 the	 fact	 that	 case-control	 approaches	
assume	 that	 the	 controls	 have	 little	 or	 no	 genetic	 predisposition	 towards	 athleticism;	
however,	 it	 is	 much	 more	 likely	 that	 they	 contain	 a	 number	 of	 genetically	 predisposed	
individuals	 who	 are	 simply	 inactive	 and	 therefore	 not	 meeting	 their	 athletic	 potential	
(Tucker	&	Collins,	 2012).	 Furthermore,	 predisposing	 variants	 are	 often	 identified	 in	 small	
cohorts	without	replication	of	the	findings	in	secondary	cohorts	(see	Pitsiladis	et	al.,	2013	
for	 review).	 Thus	 there	 is	 a	 risk	 that	many	 of	 the	 variants	 identified	 so	 far	may	 be	 false	
positive	artefacts	of	small	cohorts	with	only	the	most	robustly	replicated	variants,	such	as	
ACTN3	R577X,	being	true	positives.	In	part,	this	problem	is	due	to	the	difficulty	in	recruiting	
large	enough	numbers	of	 elite	 athletes	who	are	a	 very	 small	minority	of	 any	population.	
Furthermore,	collectively	the	genetic	variants	rarely	explain	anything	approaching	the	50%	
of	the	variance	identified	in	the	twin	and	family	studies.	Thus,	a	gap	in	our	understanding	of	
the	relationship	between	heritability	and	performance	exists.	
Rare	Genetic	Variants	
One	possible	explanation	for	this	gap	in	understanding	is	that	we	have	yet	to	fully	consider	
the	 influence	 of	 rare	 genetic	 variants	 on	 sports	 performance.	Until	 recently,	 studies	 into	
the	 genetics	 of	 quantitative	 traits	 concentrated	 on	 common	 genetic	 variants;	 that	 is	
variants	with	a	minor	allele	frequency	in	the	population	of	>	1%.	The	rationale	for	this	was	
partly	 based	 on	 the	 common	 variant	 common	 disease	 hypothesis	 (Lander,	 1996)	 which	
postulates	 that	 quantitative	 phenotypes	 with	 a	 classic	 bell-shaped	 distribution	 are	 the	
result	 of	 the	 influence	 of	 many	 10s-100s	 of	 genes,	 each	 with	 a	 small	 influence	 on	
phenotype.	However,	there	were	also	practical	and	commercial	reasons.	Practically,	studies	
into	rare	variants	needed	very	large	cohorts	of	unrelated	individuals	to	identify	enough	rare	
homozygotes	to	study.	Also,	due	to	their	rarity,	not	all	rare	variants	have	necessarily	been	
identified	 by	 current	 DNA	 sequencing	 efforts,	 even	 now.	 Commercially,	 biotechnology	
companies	generally	produce	 technologies	 that	can	be	sold	 to	mass	markets	 to	maximise	
their	 profits	 thus	 the	 focus	 remained	 on	 common	 variants.	 However,	 with	 the	 ever	
decreasing	 cost	 and	 increasing	 speed	 of	 next	 generation	 DNA	 sequencing	 (NGS)	
(Wetterstrand,	2014)	it	is	now	feasible	to	perform	whole	genome	DNA	sequencing	on	large	
cohorts	of	 individuals	thus	 identifying	unknown	rare	variants	and	allowing	testing	of	their	
associations	with	quantitative	phenotypes.	
Rare	variants	are	already	known	to	influence	performance;	although	the	best	example	was	
not	 identified	 by	 modern	 NGS	 but	 instead	 by	 the	 more	 traditional	 and	 slower	 genetic	
method	 of	 identifying	 a	 disease-carrying	 family	 and	 following	 the	 disease	 through	 the	
generations	 of	 that	 family.	 Nonetheless	 this	 example	 highlights	 the	 potential	 of	 the	
infinitely	 higher	 throughput	 method	 of	 NGS	 to	 identify	 additional	 rare	 variants	 with	
significant	influences.	Eero	Mäntyranta	was	a	Finnish	cross	county	skier	in	the	1960s.	Cross	
country	 skiers	are	also	endurance	experts	 sharing	many	physiological	 characteristics	with	
cyclists.	Eero	Mäntyranta	collected	7	Olympic	medals,	5	World	Championship	medals	and	9	
domestic	championship	medals	making	him	a	truly	World	class	athlete	(Olympic.org,	2014).	
Several	 members	 of	 his	 extended	 family	 suffered	 from	 a	 disease	 called	 familial	
erythrocytosis-1	 (ECYT-1)	 due	 to	 a	 rare	 variant	 (rs121917830)	 of	 their	 erythropoietin	
receptors	(de	la	Chapelle,	Träskelin,	&	Juvonen,	1993).	Collectively	the	related	diseases	of	
ECYT1-4	occur	at	a	frequency	of	less	than	1	in	100,000	(Hussein,	Percy,	&	McMullin,	2012)	
so	 rs121917830	 is	 a	 rare	 variant	 by	 any	 standard	 although	 precise	 allele	 frequency	
information	on	rs121917830	is	not	available.	Normally,	erythropoietin	(EPO)	is	produced	in	
response	 to	 low	 oxygen	 levels.	 It	 activates	 the	 EPO	 receptor	 (EPOR)	 resulting	 in	 the	
production	of	more	red	blood	cells	and	thus	an	increase	in	the	oxygen	carrying	capacity	of	
the	blood.	Individuals	with	ECYT-1	have	variant	EPORs	that	are	effectively	hypersensitive	to	
EPO;	thus	they	have	an	increased	red	blood	cell	count	and	the	oxygen	carrying	capacity	of	
their	blood	can	be	increased	by	up	to	50%.	The	extra	blood	cells	thicken	their	blood	putting	
them	 at	 risk	 of	 abnormal	 blood	 clots	 which	 can	 cause	 life	 threatening	 complications;	
however,	if	they	exercise,	the	additional	oxygen	carrying	capacity	gives	them	an	advantage	
at	endurance	events;	similar	to	the	effects	of	injecting	the	drug	EPO	(Durussel	et	al.,	2013).	
It	 is	 this	 kind	 of	 natural	 variation	 that	 creates	 the	 necessity	 for	 a	 complex	 biological	
passport	rather	than	a	simple	permissible	threshold.	Such	a	variant	would	also	likely	be	of	
benefit	 to	 individuals	 involved	 in	 elite	 cycling.	 Paradoxically,	 those	 carrying	 rs121917830	
variation	are	likely	to	derive	less,	if	any,	benefit	from	the	illicit	use	of	EPO.	
Rare	variants	are	expected	to	have	larger	influences	on	phenotype	than	common	variants	
in	part	explaining	why	they	remain	rare	since	 larger	 influences	on	phenotype	are	 likely	to	
be	 less	 well	 tolerated.	 So	 far,	 rare	 variant	 studies	 have	 concentrated	 on	 major	 human	
diseases	 such	as	 cancer	 (Stadler,	 Schrader,	Vijai,	Robson,	&	Offit,	 2014)	or	 cardiovascular	
disease	(Peloso	et	al.,	2014).	However,	typically	these	rare	variants	have	been	in	the	same	
genes	 as	 the	 established	 common	 variants	 and	 have	 not	 furthered	 our	 understanding	 of	
these	phenotypes	as	much	as	was	anticipated.	It	seems	likely	that	when	NGS	is	applied	to	
elite	cyclists	or	performance	phenotypes	that	some	rare	variants	with	important	influences	
will	be	identified	although	it	seems	equally	unlikely	that	this	will	be	the	whole	story.	
Epigenetic	Variation	
Another	source	of	heritable	variation	that	may	help	explain	the	gap	in	our	understanding	is	
through	epigenetic	coding.	Physiological	epigenetics	is	a	rapidly	developing	field	with	great	
promise.	 Epigenetics	 includes	 histone	 modifications,	 DNA	 methylation	 and	 RNA	
interference	 by	 non-coding	 RNAs	 such	 as	microRNA	 (miRNA).	 This	 review	will	 only	 cover	
miRNAs	although	both	histone	modifications	and	DNA	methylation	are	involved	in	control	
of	gene	expression	and	are	also	likely	important	to	sports	performance	(Ling	&	Rönn,	2014;	
McGee,	 Fairlie,	 Garnham,	 &	 Hargreaves,	 2009).	 Like	 genetic	 variants,	 epigenetic	
modifications	are	heritable	(Rissman	&	Adli,	2014);	however,	unlike	genetic	variants,	 they	
are	 also	 malleable	 within	 an	 individual	 (Baggish	 et	 al.,	 2011;	 Barrès	 et	 al.,	 2012).	 Thus,	
understanding	epigenetic	modifications	may	not	only	help	us	understand	which	individuals	
have	 the	most	sporting	potential	but	also	help	understand	how	they	can	be	manipulated	
through	appropriate	training	and	dietary	regimes	that	may	help	improve	performance.	
The	traditional	view	of	molecular	biology,	encapsulated	in	the	central	dogma	(Crick,	1970)	
held	 that	 proteins	were	 easily	 the	most	 important	 functional	molecule	 in	 a	 cell	 and	 that	
RNA	 was	 mostly	 an	 intermediate	 step	 between	 DNA	 and	 proteins	 (excepting	 tRNA	 and	
rRNA).	 However,	 recent	 data	 from	 the	 ENCODE	 project	 (Bernstein	 et	 al.,	 2012)	 suggests	
that	whilst	approximately	75%	of	the	genome	is	transcribed	into	RNA	(Djebali	et	al.,	2012)	
only	a	small	proportion	of	that	(1-3%)	is	directly	involved	in	protein	coding	(Bernstein	et	al.,	
2012).	 Thus	 the	 vast	majority	 of	 RNA	 is	 non-protein-coding.	However,	much	 of	 this	 non-
protein-coding	 RNA	 appears	 to	 have	 functions	 which	 are	 only	 now	 beginning	 to	 be	
explored.	A	number	of	recent	studies	in	exercise	genomics	have	recognised	the	importance	
of	non-coding	RNAs,	specifically	miRNAs	(Kirby	&	McCarthy,	2013).	miRNAs	are	involved	in	
post-transcriptional	control	of	messenger	RNA	(mRNA)	either	by	inhibiting	their	translation,	
or	 by	 targeting	mRNAs	 for	 degradation	 (Guay,	 Roggli,	Nesca,	 Jacovetti,	&	Regazzi,	 2011).	
Each	miRNA	can	bind	multiple	mRNAs	and	each	mRNA	can	be	bound	by	multiple	miRNAs;	
therefore,	miRNAs	 comprise	 a	 highly	 complex	 network	 of	 regulators	 that	 fine	 tune	 gene	
and	 protein	 expression.	 miRNAs	 have	 been	 shown	 to	 be	 involved	 in	 muscle	 cell	
development	 (Luo,	Nie,	&	Zhang,	2013),	 respond	 to	exercise	both	acutely	and	chronically	
(Russell	 et	 al.,	 2013)	 and	 be	 predictive	 of	 response	 to	 training	 (Davidsen	 et	 al.,	 2011).	
Intriguingly,	miRNAs	 also	 have	 been	 found	 at	 stable	 levels	 in	 plasma	 (Chen	 et	 al.,	 2008;	
Mitchell	 et	 al.,	 2008).	 Plasma	 miRNAs	 have	 been	 shown	 to	 both	 respond	 to	 exercise	
(Baggish	 et	 al.,	 2011;	 Davidsen	 et	 al.,	 2011)	 and	 be	 dysregulated	 in	 disease	 (Chen	 et	 al.,	
2008;	Mitchell	et	al.,	2008).	There	also	is	growing	evidence	that	plasma	miRNAs	are	taken	
up	by	target	 tissues	and	may	be	 involved	 in	cell-cell	communication	 (Rayner	&	Hennessy,	
2013).	By	nature	of	their	 location	 in	the	circulation,	plasma	miRNAs	have	the	potential	to	
fine	tune	the	gene	expression	and	protein	translation	of	multiple	genes	in	multiple	tissues	
and	thus	may	have	influence	in	coordinating	the	whole	body	response	to	exercise	such	as	
cycling.	 miRNAs,	 mRNA	 and	 proteins	 comprise	 a	 very	 complex	 system	 regulating	 the	
function	of	cells.	This	 type	of	complexity	can	only	be	captured	 in	systems	biology	models	
and	 future	 research	 should	 endeavour	 to	 create	 such	models	 for	 exercise	phenotypes	 to	
build	 a	 complete	 understanding	 of	 the	 determinants	 of	 cycling	 performance	 and	 sports	
performance	in	general.	
Elite	Athlete	Cohorts	
A	 final	 source	 of	 the	 gap	 in	 our	 understanding	 of	 the	 heritability	 of	 cycling	 and	 exercise	
performance	may	be	due	to	the	specific	cohorts	and	phenotypes	within	those	cohorts	that	
have	 so	 far	 been	 used.	 Collecting	 large	 cohorts	 is	 time-consuming	 and	 elite	 athletes	 are	
rare;	 elite	 cyclists	 even	 rarer.	 Thus,	 collecting	 large	 enough	 numbers	 of	 them	 for	
comprehensive	studies	is	difficult.	Furthermore,	quantitative	measurements	allow	the	use	
of	more	powerful	statistical	techniques.	However,	elite	athletes	have	strict	training	regimes	
and	 are	 generally	 unwilling	 to	 come	 to	 the	 laboratory	 for	 detailed	 physiological	 testing,	
training	interventions	or	invasive	procedures	that	may	impede	their	training	in	the	ensuing	
days.	A	partial	answer	to	this	may	be	to	pool	our	efforts	by	combining	existing	cohorts	of	
athletes	 for	 genome	 wide	 association	 studies	 (GWAS)	 or	 NGS	 studies	 with	 subsequent	
replication	in	existing	secondary	cohorts.	 Initial	findings	from	such	efforts	show	promising	
results.	With	 this	objective	 in	mind,	 two	consortia	have	recently	been	 formed	to	conduct	
the	first	GWAS	of	elite	athletic	performance	using	existing	athlete	cohorts,	summarised	in	
Table	 2	 (and	described	 in	 Pitsiladis	 et	 al.,	 2013):	 the	PowerGene	 consortium	and	GAMES	
Consortium	(Genomic	Variants	Associated	with	Elite	Endurance	Athlete	Status).	Preliminary	
findings	 show	 promising	 odds	 ratios	 and	 a	 trend	 towards	 the	 conventional	 GWAS	
significance	 threshold	 at	p	 ≤	 5	 x	 10-8.	 Further	 validation	 of these	 signals	 in	 independent	
cohorts	 will	 be	 required,	 and	 any	 replicated	 SNPs	 taken	 forward	 for	 fine-mapping	 /	
targeted	 re-sequencing	 and	 functional	 studies	 to	 uncover	 the	 underlying	 biological	
mechanisms.	Both	of	these	consortia	are	now	part	of	the	much	larger	Athlome	Consortium	
(http://www.athlomeconsortium.org/)	which	will	facilitate	replication	and	further	analyses	
of	their	signals	as	well	as	foster	new	discoveries.	
Conclusions	
To	move	performance	genetics	and	in	particular	cycling	performance	genetics	forward	we	
need:	 (1)	 to	 collect	 larger	 cohorts	 of	 elite	 athletes	 and	 in	 particular	 cyclists	 as	 well	 as	
persuade	 them	 of	 the	 importance	 of	 collecting	 detailed	 phenotypic	 information;	 (2)	 to	
collaborate	to	pool	existing	cohorts	together;	(3)	when	possible	collect	additional	samples	
such	as	blood,	plasma	and	 tissue	 that	will	 allow	 future	epigenetic	analyses;	 (4)	 to	pursue	
cutting	 edge	 technologies	 such	 as	 next	 generation	 sequencing,	 transcriptomics	 and	
proteomics;	and	(5)	to	integrate	all	these	results	into	systems	biology	models.	
Finally,	 can	 anyone	 become	 champion	 of	 the	 Tour	 de	 France?	 For	 this	 to	 happen	 an	
individual	must	possess	the	right	genetic	and	epigenetic	variation	to	display	natural	talent	
at	cycling,	the	right	genetic	and	epigenetic	variation	to	be	able	to	respond	to	appropriate	
training	and	do	the	training	with	the	right	 team	supporting	them	 in	 the	right	way.	This	 is	
not	 an	 either	 /	 or	 situation.	 Champions	 of	 the	 Tour	 de	 France	 are	 both	 born	 and	made:	
genetic	and	epigenetic	variations	provide	the	potential	 in	some	 individuals	but	 they	must	
then	unlock	that	potential	with	appropriate	training	and	lifestyle.	
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Table(s)	with	caption(s)	(on	individual	pages)	
GENE	 VARIANT	 STUDY	DESIGN	 ATHLETES	 ETHNICITY	
&	GENDER	
ATHLETES	
(CYCLISTS)	
CONTROLS	 ASSOCIATION	(REFERENCE)	
ACE	 rs4646994	
(intron	16	
indel)	
Case-control	 Professional	cyclists,	long-
distance	runners	and	handball	
players	
Spanish	
males	
60	(25)	 400	 I-allele	over-represented	in	athletes	compared	
to	controls	(Alvarez	et	al.,	2000).	
	 	 Case-control	 Professional	cyclists	and	
Olympic-class	endurance	
runners	
Spanish	
males	
77	(50)	 119	 DD	genotype	over-represented	in	cyclists	
compared	to	controls	or	runners.	D-allele	over-
represented	in	cyclists	compared	to	runners	
(Lucía	et	al.,	2005).	
	 	 Case-control	 Mixed	endurance	and	power	or	
sprint	sports	
Iranian	
males	
156	(37)	 163	 D-allele	over-represented	in	cyclists	compared	
to	controls	(Shahmoradi,	Ahmadalipour,	&	
Salehi,	2014).	
	 	 Case-control	 Professional	cyclists,	Olympic-
class	endurance	runners	and	
World	class	rowers	
Spanish	
males	
141	(50)	 123	 II	under-represented	in	rowers	compared	to	
whole	cohort	(Muniesa	et	al.,	2010).	
	 	 Case-control		
Quantitative	
muscle	power	
Endurance,	power	and	mixed	
athletes	
Lithuanian	
males	and	
females	
193	(12)	 250	 DD	genotype	over-represented	in	endurance	
compared	to	power	athletes.	DD	genotype	
lower	power	than	II	genotype	(Ginevičienė,	
Pranckevičienė,	Milašius,	&	Kučinskas,	2010).	
ACTN3	 rs1815739	
(p.R577X)	
Case-control	
Quantitative	𝑉𝑂!!"#	data	 Professional	cyclists	and	Olympic-class	endurance	runners	 Spanish	males	 102	(50)	 123	 No	association	with	endurance	(Lucia	et	al.,	2006).	
	 	 Case-control	 Endurance-oriented	athletes	
including	road	cyclists	
Russian	
males	and	
females	
456	(34)	 1211	 C-allele	(577X)	under-represented	in	endurance	
athletes	(Ahmetov,	Druzhevskaya,	et	al.,	2010).	
	 	 Case-control	 Professional	cyclists,	Olympic-
class	endurance	runners	and	
World	class	rowers	
Spanish	
males	
141	(50)	 123	 No	association	with	endurance	(Muniesa	et	al.,	
2010).	
	 	 Case-control		
Quantitative	
muscle	power	
Endurance,	power	and	mixed	
athletes	
Lithuanian	
males	and	
females	
193	(12)	 250	 No	association	with	athlete	group	or	power	
(Ginevičienė,	Pranckevičienė,	Milašius,	&	
Kučinskas,	2010).	
ADRB3	 rs4994	
(p.W64R)	
Case-control	 Professional	cyclists,	Olympic-
class	endurance	runners	and	
power	athletes	
Spanish	
males	
153	(50)	 100	 C-allele	(64R)	over-represented	in	endurance	
athletes	compared	to	controls	(Santiago	et	al.,	
2011).	
AGT	 rs699	 Case-control	 Professional	cyclists,	Olympic- Spanish	 163	(50)	 119	 No	association	with	endurance.	C-allele	(235T)	
(p.M235T)	 class	endurance	runners	and	
power	athletes	
males	 may	favour	power	performance	(Gomez-
Gallego	et	al.,	2009).	
	 	 Case-control	 Professional	cyclists,	long-
distance	runners	and	handball	
players		
Spanish	
males	
60	(25)	 400	 No	association	with	endurance	(Alvarez	et	al.,	
2000).	
AGTR1	 rs12721277	
(c.*82G>A)	
Case-control	 Professional	cyclists,	long-
distance	runners	and	handball	
players		
Spanish	
males	
60	(25)	 400	 No	association	with	endurance	(Alvarez	et	al.,	
2000).	
AMPD1	 rs17602729	
(p.Q45X)	
Case-control	
Quantitative	𝑉𝑂!!"#	data	 Professional	cyclists	and	Olympic-class	endurance	runners	 Spanish	males	 104	(50)	 100	 C-allele	(45Q)	over-represented	in	endurance	athletes	although	do	not	have	higher	𝑉𝑂!!"#	(Rubio	et	al.,	2005).	
	 	 Case-control	 Professional	cyclists,	Olympic-
class	endurance	runners	and	
World	class	rowers	
Spanish	
males	
141	(50)	 123	 No	association	with	endurance	(Muniesa	et	al.,	
2010).	
	 	 Case-control		
Quantitative	
muscle	power	
Endurance,	power	and	mixed	
athletes	
Lithuanian	
males	and	
females	
204	(12)	 260	 TT	genotype	(45XX)	absent	from	athlete	group.	
T-allele	under-represented	in	power	athletes	
compared	to	controls.	CC	genotype	associated	
with	muscle	power	(Ginevičienė	et	al.,	2014).	
CKMM	 rs8111989	
(g.45809208
T>C)	
Case-control	 Professional	cyclists	and	
Olympic-class	endurance	
runners	
Spanish	
males	
77	(50)	 119	 No	association	with	endurance	(Lucía	et	al.,	
2005).	
	 	 Case-control	 Professional	cyclists,	Olympic-
class	endurance	runners	and	
World	class	rowers	
Spanish	
males	
141	(50)	 123	 No	association	with	endurance	(Muniesa	et	al.,	
2010).	
GDF8	 rs1805086	
(p.K153R)	
Case-control	 Professional	cyclists,	Olympic-
class	endurance	runners	and	
World	class	rowers	
Spanish	
males	
141	(50)	 123	 No	association	with	endurance	(Muniesa	et	al.,	
2010).	
HFE	 rs1799945	
(p.H63D)	
Case-control	 Professional	road	cyclists	with	
hyperferritinemia	
French	
males	
77	(77)	 254	 G-allele	(63D)	over-represented	in	cyclists	
compared	to	controls	(Deugnier	et	al.,	2002).	
	 	 Case-control	
Quantitative	𝑉𝑂!!"#	data	 Professional	cyclists	and	Olympic-class	endurance	runners	 Spanish	males	 65	(50)		 134	 G-allele	(63D)	over-represented	in	endurance	athletes	although	do	not	have	higher	𝑉𝑂!!"#	(Chicharro	et	al.,	2004).	
IL6	 rs1800795	
(c.-174C>G)	
Case-control	 Professional	cyclists,	Olympic-
class	endurance	runners	and	
power	athletes	
Spanish	
males	
153	(50)	 100	 No	association	with	endurance.	GG	genotype	
and	G-allele	over-represented	in	power	
athletes	compared	to	controls	or	endurance	
athletes	(Ruiz	et	al.,	2010).	
IL15RA	 rs2228059	
(p.N12T)	
Case-control	 Mixed	endurance	and	sprint-
power	sports	
European	
Australian	
308	(73:	43	
endurance;	
258	 A-allele	(12N)	over-represented	in	all	cyclists	
compared	to	controls	(Pistilli	et	al.,	2011).	
males	and	
females	
30	sprint-
power)	
MtDNA	 Haplogroup	 Case-control	 Professional	cyclists,	Olympic-
class	endurance	runners	and	
power	athletes	
Spanish	
males	
153	(50)	
	
478	 V	haplogroup	over-represented	in	elite	
endurance	athletes	compared	to	controls	
(Nogales-Gadea	et	al.,	2011).	
NOS3	 rs2070744	
(c.-786C>T)	
Case-control	 Professional	cyclists,	Olympic-
class	endurance	runners	and	
power	athletes	
Spanish	
males	
153	(50)	
	
100	 No	association	with	endurance.	TT	genotype	
and	T-allele	over-represented	in	power	athletes	
compared	to	controls	or	endurance	athletes	
(Gómez-Gallego	et	al.,	2009).	
PER3	 VNTR	(54	bp	
repeat)	
Case-control	 Cyclists,	runners	and	Ironman	
triathletes	
South	
African	
males	of	
European	
descent	
532	(125)	 96	 PER3(5/5)	over-represented	in	all	athletes	
compared	to	controls	(Kunorozva,	Stephenson,	
Rae,	&	Roden,	2012).	
PPARA	 rs4253778	
(c.2528G>C)	
Case-control		
Quantitative	
muscle	power	
Endurance,	power	and	mixed	
athletes	
Lithuanian	
males	and	
females	
193	(12)	 250	 C-allele	over-represented	in	all	athletes	
compared	to	controls	(Ginevičienė,	
Pranckevičienė,	Milašius,	&	Kučinskas,	2010).	
PPARD	 rs2016520	
(c.-87C>T)	
Case-control	 Endurance	and	power	athletes	
from	a	range	of	sports	
Russian	
males	and	
females	
1256	(108)	 610	 C-allele	over-represented	in	endurance	athletes	
(Ahmetov,	Astratenkova,	&	Rogozkin,	2007)	
PPARGC1A	 rs8192678	
(p.G482S)	
Case-control	
Quantitative	𝑉𝑂!!"#	data	 Professional	cyclists	and	Olympic-class	endurance	runners	 Spanish	males	 104	(50)	 164	 G-allele	(482G)	predicts	exceptional	endurance	capacity	(Lucia	et	al.,	2005).	
	 	 Case-control	 Professional	cyclists,	Olympic-
class	endurance	runners	and	
World	class	rowers	
Spanish	
males	
141	(50)	 123	 No	association	with	endurance	(Muniesa	et	al.,	
2010).	
	 	 Case-control		
Quantitative	
muscle	power	
Endurance,	power	and	mixed	
athletes	
Lithuanian	
males	and	
females	
193	(12)	 250	 482S	homozygotes	had	higher	power	
performance	(Ginevičienė,	Pranckevičienė,	
Milašius,	&	Kučinskas,	2010).	
TFAM	 rs1937	
(p.S12T)	
Case-control	
Quantitative	𝑉𝑂!!"#	data	 Endurance	and	power	athletes	from	a	range	of	sports	 Russian	 1537	(109)	 1113	 C-allele	(12T)	over-represented	in	endurance	athletes	(Ahmetov,	Popov,	Missina,	Vinogradova,	&	Rogozkin,	2010).	
VEGFA	 rs2010963	
(c.-634C>G)	
Case-control	
Quantitative	𝑉𝑂!!"#	data	 Endurance	and	power	athletes	from	a	range	of	sports	 Russian	males	and	females	 670	(110)	 1073	 C-allele	over-represented	in	endurance	athletes	(Ahmetov	et	al.,	2008).	
VEGFR2	 rs1870377	
(p.Q472H)	
Case-control	
Quantitative	𝑉𝑂!!"#	data	 Endurance	and	power	athletes	from	a	range	of	sports	 Russian	males	and	females	 471	(11)	 603	 A-allele	(472Q)	with	endurance-related	phenotypes	(Ahmetov	et	al.,	2009).	
Table	1.	Candidate	gene	association	studies	comparing	cyclists	to	controls	showing	study	characteristics	and	findings. 
STUDY	 PRIMARY	DESIGN	 PARTICIPANTS	
GENATHLETE	 Candidate	gene	case-
control	multicentre	study	
~300	 Endurance	athletes	with	high	𝑉𝑂!!"#	
~300	 Untrained	controls	with	low	to	average	𝑉𝑂!!"#	
RUSSIAN	
COHORT	
Candidate	gene	case-
control	study	involving	24	
different	athletic	
disciplines	
1423	 Russian	 endurance	 athletes	 of	 regional	 or	 national	 competitive	
standards	
1242	 Russian	controls	
EAST	
AFRICAN	
COHORT	
Candidate	gene	case-
control	study	
291	 Kenyan	endurance	athletes	of	national	/	international	standard	
85	 Kenyan	controls	
76	 Ethiopian	endurance	athletes	from	junior	/	senior	national	athletic	
teams	
315	 Ethiopian	controls	
JAMAICAN	
AND	USA	
COHORT	
Candidate	gene	case-
control	study	and	GWAS	
116	 Jamaican	 sprint	 athletes	 of	 national/	 international	 competitive	
standard	
311	 Jamaican	controls	
114	 African-American	 sprint	 athletes	 of	 national	 /	 international	
competitive	standard	
191	 African-American	controls	
AUSTRALIAN	
COHORT	
Candidate	gene	case-
control	study	involving	14	
different	sports	
429	 Elite	white	athletes	
436	 White	controls	
JAPANESE	
COHORT	
Candidate	gene	case-
control	study	and	GWAS	
717	 Japanese	athletes	of	national	/	international	competitive	standard	
including	 381	 track	 and	 field	 athletes,	 166	 swimmers	 and	 170	
Olympians	from	various	sports	
814	 Japanese	controls	
EUROPEAN	
AND	ASIAN	
SWIMMING	
COHORT	
Candidate	gene	case-
control	study	
200	 Caucasian	swimmers	of	world-class	status	
158	 Japanese	of	national	competitive	standards	
649	 Japanese	controls	
168	 Taiwanese	 swimmers	 of	 national	 /	 international	 competitive	
standards	
603	 Taiwanese	controls	
SPANISH	
COHORT	
Candidate	gene	case-
control	study	
100	 Spanish	male	endurance	athletes	of	world-class	status	
54	 Spanish	male	rowers	of	world-class	status	
108	 All-time	best	Spanish	Judo	male	athletes	
88	 Swimmers	of	national	level	
53	 Power	athletes	of	national	/	international	competitive	standards	
343	 Spanish	controls	
ISRAELI	
COHORT	
Candidate	gene	case-
control	study	
74	 Israeli	endurance	athletes	of	national	 /	 international	 competitive	
standard	
81	 Power	athletes	of	national	/	international	competitive	standard	
240	 Israeli	controls	
CHINESE	
COHORT	
Candidate	gene	case-
control	study	
241	 Chinese	(HAN)	endurance	athletes	
504	 Chinese	(HAN)	controls	
POLISH	
COHORT	
Candidate	gene	case-
control	study	involving	20	
different	athletic	
disciplines	
660	 Polish	athletes	of	national	/	international	competitive	standard	
684	 Polish	controls	
LITHUANIAN	
(Kaunas)	
COHORT	
Candidate	gene	
association	study	
involving	19	different	
athletic	disciplines	
performing	over	20	
groups	of	phenotypic	
measurements	
126	 Strength-power	 athletes	 of	 regional	 /	 national	 /	 international	
standard	including	Olympic	athletes	
84	 Endurance	athletes	of	regional	/	national	/	international	standard	
including	Olympic	athletes	
197	 Lithuanian	controls	
LITHUANIAN	
(Vilnius)	
COHORT	
Candidate	gene	
association	study	
involving	15	different	
athletic	disciplines	
performing	3	groups	of	
phenotypic	
measurements	
59	 Endurance	athletes	of	international	/	regional	standard	
71	 Strength	and	speed	athletes	of	international	/	regional	standard	
431	 Mixed	team	sports	athletes	of	international	/	regional	standard	
260	 Lithuanian	controls	
Table	2.	Major	study	cohorts	in	genetics	of	elite	performance	(see	Pitsiladis	et	al.,	2013).	
